Trial Profile

A phase 2 randomized, double-blind, placebo-controlled trial of TNX-1900 in patients with social anxiety disorder

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 25 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Oxytocin (Primary)
Indications Social phobia
Focus Proof of concept; Therapeutic Use

Most Recent Events

10 Aug 2023 According to a Tonix Pharmaceuticals media release, Angela Fang is the principle investigator of this trial.
10 Aug 2023 According to a Tonix Pharmaceuticals media release, first participant was enrolled in a Phase 2 investigator-initiated, proof-of-concept study of TNX-1900 for enhancing social safety learning in social anxiety disorder (SAD).
10 Aug 2023 According to a Tonix Pharmaceuticals media release, Tonix entered into an agreement with the University of Washington to examine the potential role of TNX-1900 in enhancing vicarious extinction learning in SAD, compared to healthy controls

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com